SCNI News & Events

The major averages closed broadly higher as investors weigh the odds that the U.S.-Iran war could potentially be over soon. On one hand, there are reported to be talks around a potential 45-day ceasefire between the U.S. and Iran, which has helped stabilize sentiment and even push oil lower at moments. On the other hand, renewed threats around striking Iranian infrastructure are keeping crude elevated around the $110 range and preventing a full risk-on move. Adding to tensions were comments by President Trump this afternoon that Iran "could be taken out in one night," and that night "might" be this Tuesday if Iran does not reach a deal with the U.S.Meanwhile, Monday was the first trading day since the U.S. Bureau of Labor Statistics announced its jobs report for March. The U.S. added 178,000 jobs last month, the biggest gain since December 2024, with the unemployment rate falling to 4.3%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:NeurocrineSoleno Therapeuticsfor $53 per share in cashAn Italian court ruled that Netflixunlawfully increased prices,WWannounced the establishment of theOracleannounced the appointment of Hilary Maxson as CFO, which Barclays views as aMarch U.S. nonfarm payrolls rose 178,000, with the unemployment rate2. WALL STREET CALLS:Netflixto Buy at Goldman SachsCarvanato Neutral at BofAKratos Defenseto Buy at Jefferies on missile demandTwilioto Buy at JefferiesBofADow Inc.and LyondellBasellto Underperform3. AROUND THE WEB:Metawill launch AI models with an open source license, Axios reportsA Meta-backeddata center campus is seeking $3B in construction loans for an off-grid project, FT reportsLiberty Globalhas tabled an offer to buy a London-based franchise that would participate in a new European basketball league being set up by the National Basketball Association, Sky News saysParamounthas received signed equity commitments of close to $24B from three sovereign-wealth funds led by Saudi Arabia to help back its takeover of Warner Bros. Discovery, WSJ reportsUniversal Pictures'and Nintendo's"The Super Mario Galaxy Movie" has earned an estimated $372.5M in worldwide box-office sales, the biggest opening of 2026 so far, WSJ says4. MOVERS:FuboTVgains after providingand FY28AMC Entertainmentincreases after delivering aover the 5-day Easter weekendSeagatehigher after Morgan Stanley named theViridianfalls after Amgen'sPhase 3 trial of Tepezza met itsAtlas Energylower after announcing a5. EARNINGS/GUIDANCE:Sunshine Biopharma, with EPS and revenue higher year-over-yearScinai ImmunotherapeuticstargetedDeFi Technologies, with the company stating, "These results reflect the strength of the business model we have built"Delta Air Linesis expected toon April 8, 2026Constellation Brandsis expected toon April 8, 2026INDEXES:The Dow rose 165.21, or 0.36%, to 46,669.88, the Nasdaq gained 117.16, or 0.54%, to 21,996.34, and the S&P 500 advanced 29.14, or 0.44%, to 6,611.83.

The major averages were broadly higher near noon as investors weigh the odds that the U.S.-Iran war could potentially be over soon. Over the weekend and into today, headlines have pulled in opposite directions. On one hand, there are reported to be discussions around a potential 45-day ceasefire between the U.S. and Iran, which has helped stabilize sentiment and even push oil lower at moments. On the other hand, renewed threats around striking Iranian infrastructure are keeping crude elevated around the $110 range and preventing a full risk-on move.Meanwhile, Monday is the first trading day since the U.S. Bureau of Labor Statistics announced its jobs report for March. The U.S. added 178,000 jobs last month, the biggest gain since December 2024, with the unemployment rate falling to 4.3%.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:NeurocrineSoleno Therapeuticsfor $53 per share in cashAn Italian court ruled that Netflixunlawfully increased prices,WWannounced the establishment of theOracle (ORCL) announced the appointment of Hilary Maxson as CFO, which Barclays views asMarch U.S. nonfarm payrolls rose 178,000, with the2. WALL STREET CALLS:Netflixto Buy at Goldman SachsCarvanato Neutral at BofAKratos Defenseto Buy at Jefferies on missile demandTwilioto Buy at JefferiesBofADow Inc.and LyondellBasellto Underperform3. AROUND THE WEB:Mazdais halting production of vehicles made for the Middle East until May following the effective closure of the Strait of Hormuz, Nikkei Asia saysA Meta-backeddata center campus is seeking $3B in construction loans for an off-grid project, FT reportsLiberty Globalhas tabled an offer to buy a London-based franchise that would participate in a new European basketball league being set up by the National Basketball Association, Sky News saysParamounthas received signed equity commitments of close to $24B from three sovereign-wealth funds led by Saudi Arabia to help back its takeover of Warner Bros. Discovery, WSJ reportsUniversal Pictures' and Nintendo's"The Super Mario Galaxy Movie" has earned an estimated $372.5M in worldwide box-office sales, the biggest opening of 2026 so far, WSJ says4. MOVERS:FuboTVgains afterfor FY26 and FY28AMC Entertainmentincreases after delivering aover the 5-day Easter weekendSeagatehigher after Morgan Stanley named the company as aViridianfalls after Amgen'sPhase 3 trial of Tepezza met itsAtlas Energylower after announcing a5. EARNINGS/GUIDANCE:Sunshine Biopharma, with EPS and revenue higher year-over-yearScinai Immunotherapeuticstargeted $5M inDeFi Technologies, with the company stating, "These results reflect the strength of the business model we have built"Delta Air Linesis expectedon April 8, 2026Constellation Brandsis expectedon April 8, 2026INDEXES:Near midday, the Dow was up 0.20%, or 93.54, to 46,598.21, the Nasdaq was up 0.42%, or 91.62, to 21,970.80, and the S&P 500 was up 0.28%, or 18.18, to 6,600.87.

Building on the new structure, the company's 2026 objectives include: CDMO Platform: Scaling operations across both sites and expanding the customer base in the U.S. and Europe; Leveraging the Recipharm collaboration to support programs beyond early-stage development; Targeting approximately $5 million in CDMO revenues in 2026. R&D: Advancing PC111 as the company's lead value-driving program; Progressing the IL-17 undisclosed second target bi-specific program as a key validation of the NanoAbs platform; Continuing to advance the pipeline through capital-efficient strategies, with a focus on non-dilutive funding to support early-stage development.

Scinai Immunotherapeutics announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization. Building on its previously announced acquisition of Recipharm Israel Ltd. and related commercial collaboration with Recipharm, this reorganization represents a structural transformation of the company's operating model, designed to enhance capital efficiency, improve operational focus and position each business to independently create and capture value. Following the company's previously announced acquisition of Recipharm Israel Ltd. in February 2026, which included a small-molecule drug development and manufacturing site in Yavne, the acquired entity was renamed Scinai Biopharma Services Ltd. As part of a corporate reorganization designed to consolidate CDMO activities, the company transferred all CDMO-related operations, including employees, infrastructure, manufacturing facilities, customer contracts and associated business activities, into this entity, establishing Scinai Biopharma Services Ltd. as the Company's dedicated CDMO subsidiary. Scinai Biopharma Services now operates as a fully integrated, privately held CDMO platform, wholly owned by Scinai Immunotherapeutics. The reorganization was undertaken to position each part of the business more clearly for its respective stakeholders. This structure establishes a clear separation between: Scinai Biopharma Services - a dedicated, execution-focused CDMO business, and Scinai Immunotherapeutics - a streamlined R&D organization focused on advancing innovative therapeutics.